CLSD Oct 2024 2.500 call
| Previous Close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.1500 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireClearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials a
Simply Wall St.Shareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested three years ago
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...
- GlobeNewswire
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprac
